Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivarmacitinib - Arcutis Biotherapeutics/Reistone Biopharma

Drug Profile

Ivarmacitinib - Arcutis Biotherapeutics/Reistone Biopharma

Alternative Names: ARQ 252 active ingredient - Jiangsu Hengrui Medicine; Ivarmacitinib sulfate - Arcutis Biotherapeutics/Reistone Biopharma; SHR-0302; SHR0302 base

Latest Information Update: 16 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Jiangsu Hengrui Medicine Co.; Reistone Biopharma
  • Class 2 ring heterocyclic compounds; Amides; Amines; Anti-inflammatories; Antirheumatics; Cyclopentanes; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Thiadiazoles
  • Mechanism of Action Janus kinase 1 inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Atopic dermatitis
  • Phase III Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase II/III Ankylosing spondylitis; Vitiligo
  • Phase II Alopecia areata; Crohn's disease
  • Phase I Graft-versus-host disease
  • No development reported Liver disorders; Systemic lupus erythematosus

Most Recent Events

  • 15 Jan 2024 Jiangsu Hengrui Medicine Co. plans a phase I trial for Autoimmune diseases (In Volunteers) in January 2024 (PO) (NCT06202612)
  • 09 Dec 2023 Efficacy and adverse events data from a phase I trial in Graft-versus-host-disease presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 05 Dec 2023 Preregistration for Atopic dermatitis (Topical), prior to December 2023 (Jiangsu Hengrui Medicine pipeline, December 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top